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 FOREWORD 
 
The Trent  Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Purchasing 
Authorities Chief Executives (PACE) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development, The Scottish Health Purchasing Information Centre 
(SHPIC) and The University of Birmingham Department of Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst, 
Chairman, Trent Working Group on Acute Purchasing. 
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EXECUTIVE SUMMARY 
 
Donepezil is one of a new group of selective acetylcholinesterase inhibitors which has been 
newly licensed in the UK for use for people with mild and moderate Alzheimer’s Disease. 
The drug is marketed as having an effect on the symptoms of the disease, but it has no 
effect on the underlying disease process. The cost of donepezil is approximately £1,000 per 
patient per year. 
 
Alzheimer’s Disease affects about 8% of the population over 65 years of age. It is estimated 
that the number of people with mild to moderate dementia in a population of 500,000 is 
approximately 2,400. Prevalence is expected to increase over time with the ageing of the 
population and anticipated increase in the number of people over 85 years of age. 
 
So far, evidence of efficacy is based on three randomised controlled trials of which only one, 
the Phase II trial, is published in full. The two Phase III trials, which are currently published 
in abstract form, looked at two treatments (5mg and 10mg) against placebo. A variety of 
outcome measures were used which measured changes in cognitive function and severity of 
the disease. Secondary outcome measures examined activities of daily living and quality of 
life for patients and carers. The trials examined the effects of donepezil over 12 weeks and 
24 weeks respectively. A placebo washout followed both Phase III trials which showed that 
all treatment arms returned to the same cognitive function as the placebo group after six 
weeks removal of the drug. 
 
The results of the trials showed modest improvement in cognitive function which were 
considered significant in research terms. It is unclear how much that improvement is 
translated into improvement in clinical functioning and quality of life for patients and carers. 
 
Changes in clinical condition were reported using measures of global impression of change. 
However, these changes were minimal and the reliability of the scales has not been 
established. Measures of the impact on quality of life have not been validated for this patient 
group. Further work is required to examine the impact on clinical function, activities of daily 
living, the impact on health and well-being of carers, and whether the drug can effect a 
delay in the need for hospital care.  
 
The effect of the drug is to give a slight improvement in cognitive function compared with 
placebo, and then a continued decline, delayed by approximately 12 weeks, but otherwise at 
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the same rate as the placebo group. The overall impact is a delay of progression of the 
disease of about three months. When the prescription is stopped, the effect is not sustained 
and the patient returns to the same cognitive functioning as would be expected if the drug 
had not been prescribed in the first place. 
 
There was a reported large variation in response in all arms of the trial and it has been 
reported that some patients on treatment benefited significantly more than the average 
score for their treatment arm. This raises the question about whether there is a group of 
patients with Alzheimer’s Disease who could benefit significantly more than others. The full 
trial results are required before this can be examined further. This raises potential questions 
for further research to examine the selection of a group of patients which has potential for 
greater benefit. 
 
The trials suffered from high discontinuation rates in all arms, but in particular, the treatment 
arms. This was due to mild gastro-intestinal and neurological effects caused by the 
cholinergic effects of the drug which were clearly dose-related. No serious adverse effects 
were reported. 
 
Costs include the cost of the drug and the cost of a potential increase in demand for 
specialist assessment and diagnosis. It is not clear how long people should be prescribed 
donepezil, although, the data show that the delay in symptoms can only be sustained whilst 
people are receiving treatment.  There is no evidence available  to suggest  savings in the 
NHS or other agencies.  The lack of data on potential savings and the other uncertainties 
not answered in the available research means that any calculation of cost utility would need 
to be based on some extremely broad assumptions. It is recommended that further research 
and work is carried out in this area. 
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1. INTRODUCTION 
 
1.1 Background 
 
Alzheimer's Disease (AD) is the name given to a group of dementias, a case of which was 
first described by Alois Alzheimer in 1907. It is the most prevalent category of dementia, 
possibly accounting for approximately 70% of cases. 
 
The condition is usually sporadic, but can be familial, and several relevant genetic loci have 
been elucidated. Macroscopically there is progressive ventricular dilatation and global 
cortical atrophy with marked thinning of the parahippocampal gyrus. 
 
The final common pathway in all cases seems to be the deposition of beta-amyloid protein 
in the form of neuritic plaques in the hippocampus and areas of cerebral cortex. Possibly 
secondary to plaque formation, neurofibrillary tangles form intracellularly and correlate in 
numbers to disease severity. 
 
Loss of cholinergic neurones occurs especially in the nucleus basalis of Meynert whose cells 
project to the hippocampus and cortex. Whilst other neurotransmitter systems are involved 
later, cholinergic deficits are prominent early in the disease. 
 
1.2 Incidence and Pathology 
 
Overall, dementia is a major cause of disability amongst older adults. It affects about 8% of 
people over 65 years of age, rising to over 20% in the over 80s. Approximately 70% of 
cases of dementia are due to AD, 60% of these having mild to moderate disease. 
 
The most recent compilation of  prevalence data for dementia comes from the work of 
EURODEM,
1 
the European Commission for Concerted Action on the Epidemiology and 
Prevention of Dementia. EURODEM has published age- and sex-specific prevalence 
estimates for dementia derived from 12 European population-based studies conducted or 
published since 1980. These studies have all had sample sizes sufficiently large to enable 
age- and sex-specific estimates of prevalence to be calculated. 
 
By applying the prevalence rates for all dementia using the results of the  EURODEM study 
to an average health authority with a population of 500,000, (see Table 1), there are 
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estimated to be approximately 5,725 cases of dementia. Assuming that AD is responsible 
for approximately 70% of dementia in older adults, we would expect about 4,000 cases, of 
which around 2,400 would have mild and moderate disease. 
 
Table 1: The Prevalence of Dementia Applied to a Population of 500,000  
 
Age Population Prevalence of dementiaf Dementia Expected Expected Mild and
group Male Female Dementia AD Moderate
AD
45-64 112,756 0.06% 0.06% 68 47 28
65-69 24,184 2.20% 1.10% 393 275 165
70-74 22,022 4.60% 3.90% 928 650 390
75-79 15,056 5.00% 6.70% 906 634 380
80-84 10,838 12.10% 13.50% 1,411 987 592
85+ 8,079 21.50% 26.20% 2,020 1,414 849
Total 45+ 192,935 5,725 4,008 2,405
All ages 500,000
 
 
The incidence rate of new cases of dementia is estimated to be 1% per annum in people 
aged 65 or over, and increases with age. It would be expected that there would be 800 new 
cases of dementia in the average health authority, with about 560 of these being of the 
Alzheimer's type each year. 
 
1.3 Standard Management of Alzheimer's Disease 
 
Currently, the clinical management of AD is focused on accurate diagnosis and provision of 
appropriate services to patients and carers.  Diagnostic criteria such as D.S.M. IV and 
NINCDS-ADRDA
2
 do not allow the diagnosis of AD in the presence of other brain disease 
and systemic disorders that may account for the dementia. The process of diagnosis, 
therefore, requires a search for other disorders to exclude other causes of dementia. 
 
Although the process of diagnosis may be initiated before there is any substantial need for 
support services, it is often the latter which triggers the former.  The delay in diagnosis may 
be due to the patients’ lack of awareness of problems, a perception by patients and carers 
that forgetfulness is an untreatable part of ageing, or insufficiently sensitive screening in 
primary care and elsewhere. 
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When a patient has been identified as potentially suffering from dementia, possibly AD, the 
diagnostic process usually begins, normally in a primary care setting.  Referral to secondary 
care tends to occur when specialist services are required or in cases of diagnostic difficulty. 
 
The essential elements of diagnosis are: 
 
1. A full medical history corroborated by a close relative or carer; 
2. Mental state examination including cognitive assessment; 
3. Physical examination; 
4. Routine screening blood and urine investigations; and 
5. Special investigations. 
 
1.4  Treatments for Alzheimer's Disease 
 
Donepezil hydrochloride (“Aricept”) is a distinct new piperide-based cholinesterase inhibitor. 
It is a reversible and specific inhibitor of acetylcholinesterase. Its characteristic is that it 
minimises peripheral cholinergic effects which cause side-effects in other agents. The long 
plasma half-life (up to 70 hours) not only permits once-daily dosing but also produces a 
gradual approach to steady state.  
 
Donepezil is only the first of a number of drugs likely to reach the UK market in the next two 
or three years. Over 150 drugs in development have been identified, of which over 70 are in 
Phase II or Phase III trials or in a pre-registration phase. These drugs have a wide variety of 
pharmacological actions. Whilst it is acknowledged that many will not reach the market for 
safety, efficacy or commercial reasons, many are likely to be successful. It is predicted that 
up to 10 drugs could be available in the UK within the next five years. 
 
The initial focus on new drugs for AD has been on cholinesterase inhibitors. When drugs 
from other pharmacological groups are introduced, there will be the potential for tailoring 
treatment to individuals’ clinical requirements and symptoms, and for the development of 
combination therapy, using two or three drugs to cover a spectrum of symptom control. 
Early clinical trials of combination therapy are currently being considered in the USA. 
Drugs currently under clinical development, with marketing potential in the next two to three 
years in the UK are summarised in the Appendix.  There are currently no significant clinical 
trials known to be underway directly comparing drugs for Alzheimer’s with each other. 
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There is no evidence to suggest that other cholinesterase inhibitors will have any different 
effects or activity compared to donepezil.  Eventually, differences between drugs in terms of 
symptom specificity or adverse effects may be shown.  Differences may depend on the 
degree of reversibility of the cholinesterase inhibitor effects, but this is currently only 
speculation. 
 
It is expected that rivastigmine (“Exelon”) will be marketed in the UK in early 1998, followed 
by propentofylline in mid to late 1998. Other drugs may follow in late 1998 or 1999. 
 
Propentofylline will probably have an additional indication for vascular dementia, whilst 
sabeluzole is being evaluated for its ability to slow the progression of the disease rather than 
as a palliative treatment for the symptoms. 
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2.  USE OF DONEPEZIL : SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
2.1  Available Evidence 
 
There have been three randomised controlled trials (RCT) of donepezil in the USA of which 
only one has been published in full: the Phase II trial
3
 involving 161 subjects on 1mg, 3mg 
and 5mg doses. Recently, the results from the two pivotal Phase III trials (A301 and A302)
4
 
have been completed. The first trial has been published in abstract form,
5
 so full details of 
the study methods have not been published at the time of writing this report. Patients were 
from a highly selected group, exclusion criteria including: patients without a reliable 
caregiver, insulin dependent or having unstable diabetes, having evidence of other 
psychiatric or neurological disorders, or patients with dementia complicated by other organic 
disease. 
 
Both Phase III trials were multi-centre, randomised, double-blind, placebo-controlled, three 
armed trials comparing patients on 5mg and 10mg of donepezil with a single-blind placebo 
washout at the end of the trial period. The first trial (468 patients) looked at outcome over 12 
weeks with a three week washout period. The second trial (473 patients) looked at treatment 
over 24 weeks with a six week washout phase. 
 
The Phase II trial was followed by a cohort study (A202) where patients in the trial were 
offered 7mg or 10mg after the placebo washout and were studied for up to two years. 133 
patients were enrolled in this study and only 42 completed the trial at 98 weeks. There was 
no control group. This provides the longest follow-up data for donepezil but the trial is 
unpublished. 
 
There is a European multicentre study, involving around 750 patients, which has been 
completed, but for which the data are not yet available. 
 
2.2 Outcome Measures Used 
 
Primary Outcome Variables 
1. The Alzheimer’s Disease Assessment Scale
6
 - cognitive subscale (ADAS-cog). This is 
an 11 point subscale of the ADAS with a maximum score of 70 (most severe). The 
ADAS-cog measures memory, orientation, attention, language and motor skills, but 
not everyday living skills. Although the scale shows good inter-rater and test-retest 
8 
reliability, it has been described as ‘too sensitive to change’
7
 and not conveying a 
sense of clinical relevance. In research terms, a difference of four points on the ADAS-
cog is seen as significant. Seven points will show up as slight clinical improvement 
(e.g. patient recall is slightly better, a patient being able to name a few more objects). 
The overall rate of decline in patients with AD is between 6 and 12 points per year; the 
deterioration is not linear, there being marked variation between individuals depending 
on initial severity.  
  
2. A revised version of the Clinician Interview Based Impression
7
 (CIBIC plus). This was 
used by experienced clinicians independently of the ADAS-cog. The measure includes 
caregiver interview information as well as patient assessment. The CIBIC plus is a 
seven point scale which measures a patient’s global performance in cognitive, 
behavioural and functional terms and incorporates input from the primary caregiver. 
The test-retest reliability of CIBIC plus is poor, although reliability is a problem for all 
subjective measurements. 
 
Secondary Outcome Variables 
1. The Mini Mental State Examination (MMSE).
8
 This is a well established measure for 
distinguishing between organic and functional illness in older adults. It shows good 
inter-rater and test-retest reliability. The MMSE is more sensitive than alternative 
measures at milder levels of disability, but is subject to sociodemographic bias. Levels 
of 10 to 26 correspond to mild to moderate dementia. 
  
2. Activities of Daily Living (ADL). The ADL is designed to examine the patient’s 
management of every-day living skills including selecting and preparing food, 
dressing, eating, hygiene, mobility, orientation, communication, housework and 
managing finances. 
  
3. Clinical Dementia Rating-Sum of the Boxes (CDR-SB). This is a measure of disease 
severity in dementia and has a maximum possible score of 18. The scale shows good 
reliability and is derived from semi-structured interviews with the patients and primary 
caregiver in six categories (memory, judgement, orientation, problem solving, 
community affairs, home and hobbies and personal care). 
  
4. Quality of Life scores as assessed by the patient or caregiver (QL-P and QL-C). These 
are generic measures in the following categories: working, leisure, eating, sleeping, 
9 
social contact, earning, parenting, loving, environment and self-acceptance. Some of 
these variables are less applicable to patients with AD. This scale has not been 
validated for use with patients with dementia and their carers. 
 
2.3 Review of Trial Results 
 
Table 2 below identifies the currently available studies of donepezil and summarises their 
main characteristics. It should be noted that the only trial to have been fully published at the 
time of writing this report and, consequently, to have passed through the refereering 
process for publication, is the 12 week Phase II trial. The evidence upon which this drug has 
been licensed has not yet been published in full and is only available in abstract form. 
 
Furthermore, the Phase II trial which has been published only included dosages of 1, 3 and 
5mg  in the treatment arms. Therefore, there is to date no complete, refereed information 
available on the 10mg dosage which is licensed and being marketed alongside the 5mg 
dosage.  
 
Table 2 Summary of Studies of Donepezil
9
 
 
NAME OF 
STUDY 
STUDY 
DESIGN 
DOSE NO. OF 
SUBJECTS 
DURATION STATUS 
Rogers et al 
3
 Phase II RCT 
 
1,3,5 mg 161 12 weeks’ 
treatment 
2 weeks’ 
washout 
Published 
A301 Phase III RCT 5,10 mg  468 12 weeks’ 
treatment 
3 weeks’ 
washout 
Unpublished 
A302 Phase III RCT 5,10 mg 473 24 weeks’ 
treatment 
6 weeks’ 
washout 
Published  
A202 Cohort 
extension study 
to Phase II trial 
1,3,5-7,10mg 
NB no control 
group 
133  Unpublished 
European 
multicentre 
study 
  750  Unpublished 
 
Cognitive Function 
The RCTs showed statistically significant differences between treatment and placebo 
groups in the ADAS-cog scores. All patients, including control patients, initially showed 
10 
some improvement in the ADAS-cog score which may have been due to the placebo effect 
or a learning effect in the early weeks of the trial. 
 
Figure 1 details the patient response in terms of ADAS-cog score over the 30 weeks (24 
weeks treatment, six weeks placebo washout) of Phase III trial, A302. Patients were given a 
baseline ADAS-cog assessment at randomisation, followed by further reassessments at six 
weekly intervals up to 30 weeks. Figure 1 presents the mean change from baseline scores 
for each of the three treatment arms. The treatment effect is defined as the difference 
between the mean change from baseline for the treatment group and the mean change from 
baseline for the placebo group. 
 
In this 24 week trial, the mean treatment effect at 24 weeks was -2.52 points on the 70 point 
ADAS-cog scale for the 5mg group and -2.87 for the 10mg group (p=0.0007 for 5mg and 
0.0001 for 10mg).  Pair-wise comparison of effect between the two treatment arms was not 
available, although the reported differences would not be detectable clinically. 
 
In the 12 week trial, A301 (12 weeks treatment, 3 weeks placebo washout), the mean 
treatment effect at 12 weeks was -2.48 points on the 70 point ADAS-cog scale for the 5mg 
group and -3.12 for the 10mg group (p<0.0001). 
 
Table 3 Changes in ADAS-cog in Phase III (12 week and 24 week) Trials 
 
 5mg 10mg 
A301 Treatment effect at 12 weeks (endpoint) -2.48 -3.12 
p value  p<0.0001 
A302 Treatment effect at 24 weeks (endpoint) -2.52 -2.87 
p value p=0.0007 p=0.0001 
 
After withdrawal of treatment, cognitive status declined in all patients in all the trials. In the 
24 week study no significant differences in ADAS score from baseline were maintained in 
either of the treatment arms after all patients were given six weeks of placebo.
5
 
 
A major problem with the Phase III trials is that only summary data have been made 
available. A considerable variation of response between patients in all the arms of the trials 
has been reported. This needs to be looked at in detail when the full results are made 
available. The reported range of change in the ADAS-cog score is from +10 (worsening) to  
11 
-15 in all groups. Over 80% in both treatment groups showed some response over baseline 
compared to 60% in the placebo group. 26% of the 10mg group showed an improvement of 
over seven points on the ADAS-cog compared to 15% of the 5mg group and 8% of the 
placebo group. There is anecdotal evidence that a few patients in the treatment arms 
showed considerable clinical improvement. However, there were no data to show which 
group of patients could benefit the most, or if this heterogeneity of response was 
significantly different from the placebo group. 
 
Figure 1 Effect on Cognitive Function over 24 Weeks as Measured by the 
ADAS-Cog
10
 From Trial A302. 
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Functional Status 
Clinical change in condition was assessed using the CIBIC plus scale. Table 4 shows the 
mean scores at endpoint for the various arms of the Phase III 12 week trial. At trial endpoint 
approximately twice as many donepezil treated patients demonstrated some improvement 
compared to placebo. That improvement resulted in a small statistically significant effect for 
donepezil over placebo, that is a difference of 0.29 points on the CIBIC plus scale, from a 
mean score of 4.19 for placebo group to 3.9 in the 5mg/day group in the 12 week Phase III 
trial A301.  
 
Table 4 Results of CIBIC Plus Scoring in the 12 Week Phase III Trial A301 
 
 Placebo 5mg/day 10mg/day 
12 
CIBIC plus score at 12 weeks 4.19 3.9 3.85 
p value        0.0026     0.0082 
Proportion of patients showing some 
improvement 
18% 32% 38% 
 
 
Figure 2 - Effect on Global Function over 24 Weeks as Measured by CIBIC  
           Plus.
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Severity of Disease 
In the 24 week Phase III trial, A302, a positive result is reported for the CDR-SB scores. The 
placebo group worsened compared to some small improvements over baseline for both 
treatment groups. 
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Table 5 Changes in the CDR-SB Score in 24 Week Phase III Trial A302 
 
Placebo 5mg 10mg 
0.58 -0.03 -0.02 
 
Longer-term data are available from the cohort study. The CDR-SB scores improved during 
the 12 week treatment of the RCT phase, followed by a stable period slightly worse than at 
baseline, and then gradual worsening. This is difficult to interpret in the absence of a control 
group or data on normal disease progression, as measured using the CDR-SB scale. 
 
Quality of Life 
A positive dose response was shown in the Phase II trial, although pairwise comparisons 
between groups showed no significant response. The quality of life scales used in all the 
RCTs have not been validated for this group of patients and some of the variables in the 
scale have little clinical relevance to this patient group. Further research is called for in this 
area perhaps using other measures including a full assessment of the impact on the 
caregiver.  
 
Activities of Daily Living 
No significant effects have been reported in the information currently available. 
 
Side Effects and Adverse Events 
Donepezil has not been shown to have any serious side-effects over the reported lengths of 
the trials.
5
 The main effects are cholinergic symptoms which include: headache; 
gastrointestinal symptoms; muscle cramps; insomnia; dizziness and fatigue. There are 
patient groups in which special precautions should be taken because of the cholinergic 
nature of the drug. There is a lack of evidence about concomitant use of other drugs, in 
particular psychotropic drugs, which may also be used in this patient group. 
 
The trials reported a high discontinuation rate, in particular in the treatment arms, which may 
be due to the cholinergic side-effects (Table 6) which appear to be dose-related. One factor 
may be the inability in a trial situation to titrate dosage according to response and production 
of cholinergic side-effects which may be managed better in a clinical situation.   
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Theoretical warnings about the use of donepezil because of its cholinergic effects include 
the use of anaesthesia, history of peptic ulcer, sick sinus syndrome, bladder obstruction, 
epilepsy or history of fits and history of chronic obstructive airways disease. 
 
Table 6 Comparison of Adverse Events and Numbers Discontinued in the 
Three Arms of the Phase III Trials 
 
A301 - 12 week trial 
 
 
Placebo 5mg 10mg Total 
Study population  153   157  158  468 
Completed study 93% 90% 82% 88% 
Discontinued  8% 11% 22% 14% 
Serious adverse events  9%   0%   7%   5% 
 
 A302 - 24 week trial 
 
 
Placebo 5mg 10mg Total 
Study population  162  154  157  473 
Completed study 80% 85% 68% 78% 
Discontinued 25% 18% 48% 29% 
Adverse events 34% 39% 47% 42% 
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3. COSTS AND BENEFITS 
 
3.1 Summary of Potential Costs and Benefits of Donepezil 
 
Benefits 
 
1. Improved cognitive function for patients 
with mild or moderate AD - equivalent to 
approximately a 12 week delay in 
symptom progression. 
2. Improved functional status for patient -
modest improvement in CIBIC plus score. 
3. Improved quality of life for patient -         
no clear evidence. 
4. Improved quality of life for carers -         
no objective evidence available. 
5. Reduced morbidity in carers -                 
no objective evidence available. 
Disbenefits 
 
1. Side-effects from treatment 
     See Section 3.3. 
Savings 
 
1. Possible savings made in the NHS (e.g. 
by delayed hospital entry) - no evidence 
available. 
2. Possible savings in reduced need for 
nursing/residential home care - no 
quantitative evidence available. 
3. Savings made in other areas of society 
(e.g. reduction in benefits, reduction in 
home care required) - no quantitative 
evidence available. 
4. Increased earnings by patient or carers. - 
no quantitative evidence available. 
Costs 
 
1. Cost of the drug 
 £891 per annum @ 5mg per day 
 £1,248 per annum @ 10mg per day 
2. Possible cost due to side-effects 
(hospitalisation, non-hospitalisation) - 
 no evidence available. 
3. Increased cost of diagnosis and 
assessment. 
 
 
3.2 Benefits 
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Cognitive Function 
The most reliable effects of donepezil appear to be on cognition as measured by the ADAS-
cog and MMSE. Measured improvement in cognitive status was shown in the first three to 
six months of treatment. The evidence from the studies suggests an improvement in 
cognition and a delay in cognitive decline of approximately three months. 
 
Functional Ability 
There is no significant evidence to suggest that donepezil improves functional status. 
Benefits as measured on the CIBIC plus are difficult to interpret. Although having good face-
validity, the scale is not standardised and has poor test-retest reliability. As the memory test 
components of the CIBIC carry most weight, it is not clear whether the positive effects 
reflected the cognitive benefits as measured on the ADAS-cog. The benefits were small and 
may, therefore, be of less clinical significance. 
 
Similarly, the results of the effects using the CDR-SB score, although more relevant to 
clinical status than the ADAS-cog, were small compared to placebo and cannot easily be 
taken into account in an analysis of the benefits of donepezil. 
 
The early plateau in CDR-SB in the cohort study suggests some delayed progression, 
although without controls this is difficult to interpret. Further results may be available on full 
reporting of the Phase III 24 week study, A302, to allow comparison with controls. At present 
the available published results have not shown definitively any improvement in functional 
ability using reliable methods. 
 
Quality of Life for Patients and Carers 
The results show no significant evidence as yet of improvement in quality of life either for 
patients or carers. 
 
3.3 Disbenefits 
 
Side-effects experienced in the trials showed significant minor neurological and 
gastrointestinal side-effects as shown in the table below. A lower rate of adverse effects was 
reported when the dose was titrated from 5mg to 10mg over six weeks. 
Table 7 Summary of Side-Effects Across all Trials. 
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 Treatment Placebo 
Gastrointestinal symptoms 
(diarrhoea, nausea, vomiting) 
31% 22% 
Neurological symptoms 
(headache, insomnia, dizziness, syncope) 
32% 25% 
 
Although several patients in the cohort study experienced syncope or falls, this is difficult to 
interpret without a control group. While a decrease in blood pressure was also noted in the 
24 week Phase III trial, A302, the mean change of -3.45 mmHg was not considered 
significant. 
 
3.4 Costs 
 
Cost of Donepezil 
The costs per individual per year of donepezil treatment are: 
 
5mg = £891 per annum based on 28 tablets @£68.32 
10mg = £1,248 per annum based on 28 tablets @£95.76 
 
There is a lack of evidence about the best point to stop treatment. 
Estimating the likely duration of treatment, and therefore costs, is difficult. The most widely 
quoted estimates of survival for patients with AD are between five and eight years. However, 
this may be longer with earlier diagnosis and better treatment and care. 
 
Cost of Early Referral 
It has been hypothesised that the advent of a specific treatment for patients with mild to 
moderate AD would encourage early referral and assessment. It has been recommended 
that this drug should be initiated by clinicians specialising in the mental health of older adults 
after clinical assessment. Whether this would be included as an additional cost burden 
depends on how memory clinics function. 
 
There is evidence
11  
to suggest that, even without cognitive enhancing drugs, there is benefit 
to patients and their carers of early assessment and diagnosis to allow early preparation and 
adjustment to the effects of the disease, to ensure the introduction of support services at the 
appropriate time and to exclude treatable causes of dementia. 
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3.5  Savings 
 
There is no direct evidence to suggest that any savings could be made by reduction of the 
treatment costs, reduction of hospital treatment or hospitalised care.  
 
Improvement in practical self-care skills or in support required by carers was not measured.  
  
19 
4.  OPTIONS FOR PURCHASERS AND PROVIDERS 
 
1. Not to purchase the use of donepezil. 
  
2. Not to purchase the use of donepezil and to review the situation in the light of 
research evidence becoming available on this and other drugs for dementia (see 
Appendix). 
  
3. To purchase the use of donepezil within appropriate RCTs and other studies 
designed to answer specific questions in relation to use of this drug. 
  
4. To press for appropriate research into this class of drugs to answer the questions on 
costs and benefits outlined in this report. 
  
5. To purchase donepezil within an agreed protocol defining selection and 
discontinuation criteria for the drug for a defined group of patients. 
  
6. To support open prescribing for donepezil for all patients with mild and moderate 
dementia for whom it is judged appropriate by clinicians specialising in the mental 
health care of older adults. 
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5. DISCUSSION AND CONCLUSION 
 
There is clear evidence that donepezil is efficacious in producing some improvement of 
cognitive functioning in a highly selected population with mild to moderate AD, although 
much of the evidence is as yet unpublished, except in abstract form. The evidence shows 
that it will delay the progression of the disease by approximately three months, though 
whether this is of real clinical significance is uncertain. There is no evidence, as yet, to show 
that donepezil has any effect on disease end-point or on the overall rate of decline in the 
long-term. 
 
No significant improvement in activities of daily living, or on quality of life were shown using 
the measures in the studies reviewed. Further research could usefully be caried out on 
quality of life and the impact on primary carers, using measures such as the Care Givers 
Activity Scale (CGAS). 
 
More data and analysis are required on the variations in clinical response between patients. 
Considerable variety in response was found such that small numbers of patients improved 
much more than average on the ADAS-cog scale. It may be that there is a group of patients 
who may benefit from this drug more than other patients. However, it is not possible to 
predict from the available trial data which patients could benefit the most, which would allow 
informed treatment protocols to be written, or whether this variation in disease progression 
is significantly different from the variation which occurred in the placebo group. 
 
There is no definite evidence for significant efficacy of the 5mg dose compared with 10mg, 
although the side-effects are clearly dose-dependent. The drug, however, is licensed for 
both 5mg and 10mg use. 
 
It was not possible to make any meaningful analysis in terms of costs and consequences 
given the dearth of evidence on many aspects of the cost and benefits and a large number 
of assumptions which would have to be made in order to assess these. 
 
This review illustrates once again the problems associated with the introduction of new 
drugs on the basis of limited published data on efficacy and before the results of definitive 
trials are published.  Donepezil has potentially large cost implications for the NHS because 
of the large number of eligible patients. Research questions are raised on the evidence that 
is available about the clinical efficacy of the drug, as applied to the population of people with 
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AD, and its cost-effectiveness compared to other priorities for this patient group and other 
new technologies in general. This raises questions about the criteria on which drugs receive 
a licence in the UK, including whether these should include sufficient research on efficacy 
and proof of cost-effectiveness. 
 
Recent reviews
9,12
 of the evidence which have been published have reached very similar 
views about the effectiveness of donepezil and raised similar questions about gaps in 
knowledge, which would need to be researched in order to make a definitive statement 
about the cost-effectiveness of this drug and the relative priority it should assume for health 
service expenditure. 
 
5.1 Recommendations for Further Research 
 
1. Further work is required to examine the cost and consequences of the use of 
donepezil. In particular, research is needed to examine whether there is any 
reduction in use of hospitals, nursing homes or community care associated with its 
use. 
  
2. The impact on the health and quality of life of carers should be examined further, 
possibly using validated measures such as the Care Givers Activity Scale. 
  
3. More data are required about the heterogeneity of response of patients on treatment 
compared with those on placebo, to examine whether there is a particular group of 
patients who could most benefit from use of the drug and how these patients could 
be identified. 
  
4. The long-term effects of the drug should be compared with placebo, including an 
examination of whether efficacy is maintained and for how long. 
  
5. Patients entering the trials were from a highly select group and may not be typical of 
the average patient with AD in the UK. The effect of the treatment in the average 
clinical situation, as against a trial setting, should be explored. 
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6. USE OF DONEPEZIL IN THE TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE : SUMMARY MATRIX 
 
PATIENT 
GROUP 
PATIENT CRITERIA 
(GUIDELINES NOT 
PROTOCOLS) 
ESTIMATED 
FUTURE 
ACTIVITY 
OPPORTUNITY 
FOR COST 
SAVING 
EFFECTS THAT 
COULD BE 
EXPECTED IN 
RELATION TO 
STARTING POINT 
 
COST-
EFFECTIVENESS 
Patients with 
mild and 
moderate 
dementia of 
Alzheimer's 
type. 
 
 
 
 
 
 
 
 
To be agreed, preferably on the 
basis of future research showing 
evidence of clinical effectiveness 
for particular groups of patients. 
Approximately 
2,400 adults 
over 45 years 
of age in a HA 
with a 
population of 
500,000. 
 
Potential cost 
of drug could 
be between 
£2.1 million 
and £3.0 
million 
(excluding 
assessment 
costs) if all 
eligible 
patients 
received 
treatment. 
Unlikely, as no 
evidence of 
reduced hospital 
or nursing home 
costs. 
Slight improvement in 
cognition. Possible 
slight improvement in 
function. 
 
Delay in disease 
progression 3 to 6 
months. 
Largely unproven. 
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APPENDIX - New Drugs for Alzheimer’s Disease Currently under Development and with Marketing Potential in 1997- 1999 
 
Drug name Manufacturer Pharmacological 
class 
Development 
status 
Earliest 
marketing 
Clinical summary 
Galantamine Shire Cholinesterase 
inhibitor 
Launched 
in some 
countries. 
Phase III 
Europe 
1998/99 
Therapeutic Trials:  Two clinical trials, an open pilot study in 19 patients and a 
double-blind, placebo-controlled crossover study in 79 patients with Alzheimer's 
disease (AD), used the Cognitive Drug Research (CDR) system, to evaluate changes 
in patients' cognitive function during treatment with galantamine or tacrine.  The 
double-blind study consisted of two 12-week treatment periods with placebo or tacrine 
separated by a 4-week washout period. 32 patients underwent CDR testing. In both 
trials, the CDR system provided evidence of improvement in cognitive function during 
active treatment [1]. 
In a separate study, 106 patients with mild to moderately severe AD were treated with 
galantamine (20-50mg/day PO) [duration of treatment not stated]. Significant 
improvements were seen on the Alzheimer's Disease Assessment Scale (ADAS), Mini-
Mental State Examination (MMSE) and Physicians Global Evaluation scales[2] 
167 patients with mild to moderate AD took part in a multicentre dechallenge trial. All 
patients received placebo for a 1-week run-in period, and then received galantamine 
20 mg/day for 3 weeks. After titration to determine the best individual dosage 
(50mg/day), the 112 pateints who had not had a significant placebo response or drug 
intolerance, but did have a significant response to galantamine were randomised to 
either continue with galantamine (56) or receive placebo (56) for a double-blind 10-
week maintenance/dechallenge phase. The 141 patients who completed the 3-week 
single-blind galantamine phase had a dose-related improvement in the ADAS 
cognitive subscale of 5.14 points. Responders randomised to continue with 
galantamine improved by a further 1.66 points, while those switched to placebo 
deteriorated by 1.4 points [3].  
In another study of a similar size, patients were randomised to therapy with 
galantamine 22.5, 30 or 45mg/day given tid or placebo for 10 weeks. Preliminary data 
obtained from 163 patients indicated that patients receiving the 2 highest doses of 
galantamine had better cognitive ADAS scores relative to placebo (> 5 point 
difference) [3]. 
In a 3-year open follow-up study, intermediate data for 19 patients at 24 months and 
11 patients at 36 months indicated that patients receiving galantamine 10-35 mg/day ± 
other treatments such as nootropics or antidepressants continued to show a significant 
benefit compared with patients who did not receive galantamine or any other 
acetylcholinesterase inhibitors. However, the stabilisation of ADAS cognitive score 
observed at 12 months had begun to wear off at 24 months [3]. 
 
The final results of a 3-month phase II study involving 285 patients demonstrated a 
mean improvement in ADAS cognitive score of 4.3 points in patients receiving 
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Drug name Manufacturer Pharmacological 
class 
Development 
status 
Earliest 
marketing 
Clinical summary 
galantamine 30 mg/day relative to placebo recipients (p = 0.001). The preliminary 
results of a 6-month phase III trial including 550 patients investigating the efficacy of 
galantamine 40 mg/day tid indicated highly significant improvements in cognition, as 
measured by the cognitive ADAS score, as well as in secondary efficacy measures, 
including a clinical global rating and an activities of daily living scale [4] 
Adverse Events: Agitation, Arrhythmias, Bradycardia, Diarrhoea, Dizziness, 
Hypersalivation, Sleep disorders, Nausea, Vomiting 
Metriphonate Bayer Cholinesterase 
inhibitor 
Phase III 
(Europe/ 
USA) 
1998/99 Therapeutic Trials:  High dose metrifonate improved Alzheimer's Disease 
Assessment Scale (ADAS) and Mini-Mental State Examination (MMSE) scores in a 
double-blind study involving 27 patients with Alzheimer's disease. The compound was 
safe and well tolerated [5]. 
In a multicentre randomised double-blind phase II trial in patients with probable 
Alzheimer's disease, medium and higher doses of metrifonate had significant effects 
on the ADAS-Cognitive and Clinicial Interview Based Impression of Change-Plus 
primary outcomes compared with placebo (FDC Reports Pink Sheet 1996 Aug 19). 
Adverse Events:  Agitation, Constipation, Diarrhoea, Gastrointestinal disorders, 
Malaise, Nausea, Paraesthesia, Vomiting, Cardiovascular disorders 
Milameline Hoechst 
Marion 
Roussel 
and 
Warner-
Lambert 
Muscarinic 
receptor 
agonist 
Phase III 
trials in 
Europe and 
USA 
1999/ 
2000 
Therapeutic Trials: A double-blind study in 10 elderly patients (aged 59-74 years) 
with Alzheimer's disease (NINCDS criteria) evaluated the safety and tolerance of 
multiple rising oral doses of milameline. Doses of milameline ranged from 0.5-3mg and 
were administered q6h over 19 days. The study was terminated following the fourth 
3mg dose because of concerns over safety. Trough plasma levels of milameline were 
proportional to daily dose over the range 2-10mg/day. In the light of these results, the 
maximally tolerated dose of milameline was 4-8mg/day [6]. 
Adverse Events: Diaphoresis, Hypersalivation, Nausea, Chills, Diarrhoea, Headache, 
Sweating 
Nefiracetam Daiichi 
Seiyaku 
GABA receptor 
agonists 
Pre-
registration 
(Japan) 
 Therapeutic Trials:  In a dose-finding study, a 450 mg/day dosage of nefiracetam was 
significantly more effective than a dosage of 150 mg/day among 289 evaluable 
patients with cerebrovascular disorders (81% with cerebral infarction). Patients 
received either of these regimens, or a 300 mg/day dosage, for 8 weeks in a double-
blind trial. Final global improvement ratings of ‘moderately improved or greater' were 
documented in 24.5%, 28.4% and 41.7% of patients receiving, respectively, the 150, 
300 and 450 mg/day dosages. Psychiatric symptoms responded best: these were 
‘moderately improved or greater’ in 32% of patients given the dosage of 450 mg/day 
[7]. 
Mean total scores for the Hasegawa Dementia Rating Scale (HADRS), which 
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Drug name Manufacturer Pharmacological 
class 
Development 
status 
Earliest 
marketing 
Clinical summary 
measures cognitive function, increased significantly overall in patients receiving long 
term nefiracetam therapy (up to 1 year) in 2 studies with similar protocols [8,9]. 
Nefiracetam 150mg tid (titrated to a maximum of 900 mg/day) for at least 8 weeks [8] 
or 6 months [9] was given to patients who had predominantly psychiatric symptoms, 
usually following cerebral infarction. The change in HADRS was significant in patients 
with baseline scores >10 and £30. HADRS scores worsened in 12.9% of patients in 
1 study [9]. Symptom improvement according to final global rating scores in these 
studies was ‘moderate or greater’ in 42% [8] and 46.2% [9] of patients. Improvement 
was gradual and most benefit was gained within 6 months. Nefiracetam treatment was 
rated ‘moderately useful or greater‘ in 43.6% [8] and 44.6% [9] of patients. It was rated 
‘undesirable' in 3.1% of 65 patients [9]. Improvements were greatest in psychiatric 
symptoms (‘moderately improved or greater’ in 47.4% [9] and 34% [8] of patients) and 
were least noticeable in activities of daily living [8,9]. 
Nefiracetam 150mg tid for 8 weeks was superior to placebo as measured by 
percentage of patients with a final global improvement rating of `moderate or greater' 
(32.3 vs 10.1%, p < 0.001), global usefulness (‘useful’ in 32.1 vs 10.9%, p < 0.001), 
and overall improvements in psychiatric symptoms (‘moderate or greater’ in 30.8 vs 
10.9%, p < 0.001). There were significant between-group differences favouring 
nefiracetam in the individual symptoms of apathy, emotional disturbance, interpersonal 
contact and general cognitive dysfunction [10]. 
A multicentre double-blind trial in 258 patients compared nefiracetam 150mg with 
idebenone 30mg, each given 3 times daily for 3 weeks. Patients in the nefiracetam 
group manifested more severe psychiatric symptoms at baseline. Nefiracetam 
treatment was rated ‘useful’ in 39.7% of patients, significantly more than with 
idebenone (26.9%, p < 0.05). Nefiracetam also tended to show greater efficacy as 
assessed by the final global improvement rating and overall improvement rating for 
psychiatric symptoms: for both scales 37.6% of patients given nefiracetam versus 
26.9% of idebenone recipients were judged ‘moderately improved or greater’ using 
intention-to-treat analysis. Improvement ratings for individual psychiatric symptoms 
and most other measures tended to be higher with nefiracetam but not significantly so. 
Mental function, including memory, improved in more patients treated with nefiracetam 
than with idebenone (p < 0.05) [11]. 
Adverse Events: Dizziness, Rash, Gastrointestinal disorders, Anorexia, 
Blepharoedema, Nausea, Sweating, Tinnitus 
Propentofylline Hoechst 
Marion 
Roussel 
Adenosine 
uptake 
inhibitors 
Pre-
registartion 
(Europe) 
mid 1998 Propentofylline will be addionally indicated for vascular dementia 
Therapeutic Trials: The long-term efficacy of propentofylline in patients with dementia 
has been investigated in a multicentre, randomised, placebo-controlled, double-blind 
study. Patients with DSM-III-R criteria for mild to moderate dementia of the Alzheimer's 
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Drug name Manufacturer Pharmacological 
class 
Development 
status 
Earliest 
marketing 
Clinical summary 
Phosphodieste
rase inhibitor 
Phase III 
(USA) 
Launched 
elsewhere 
(n = 170) or vascular (90) type were randomised to receive propentofylline (n = 129) 
900 mg/day tid for 12 months or placebo (131). At 12 months, the total patient 
population exhibited significant treatment differences in favour of propentofylline for 
the global measures of dementia, including the Gottfries-Bråne-Steene scale 
(p = 0.001), and the Clinical Global Impression scale item I (p < 0.01) and item II 
(0.1 < p < 0.05). Cognitive measures also revealed treatment differences in favour of 
propentofylline, including the Syndrome Short Test (p < 0.01) and the Mini-Mental 
State Examination (p = 0.001). Activities of Daily Living, as assessed by relatives and 
nursing staff, deteriorated in both patient groups, but less so in propentofylline 
recipients (p < 0.01). Treatment differences for the primary efficacy variables were 
smaller for patients with Alzheimer's disease than patients with vascular dementia, but 
all were in favour of propentofylline[12]. 
2 further trials are currently awaiting publication from which there is no prior 
information. 
Rivastigmine Novartis Cholinesterase 
inhibitor 
Pre-
registration 
(Europe, 
USA) 
early 1998 Therapeutic Trials:  Preliminary data from a phase III 26-week study involving 
699 patients with Alzheimer's disease showed that rivastigmin was well tolerated and 
associated with significant improvements in all efficacy/cognitive function measures, 
including the ADAS cog and CIBIC-Plus. 
In a phase II dose-finding study, patients with mild to moderate Alzheimer's disease 
were assigned to 1 of 3 treatment groups (2 fixed doses of rivastigmin or placebo) for 
13 weeks. Each group contained > 100 patients. A significant proportion of patients 
treated with rivastigmin showed a positive response on the Clinical Global Impression 
of Change scale. Smaller improvements were noted on 2 other scales. 
In what appears to be a separate dose-finding study, 50 patients received rivastigmin 
2-12 mg/day or placebo for 9 weeks. Although no maximum tolerated dose was 
defined, the compound was generally well tolerated up to dosages of 12 mg/day [13]. 
Data presented at the 16th World Congress of Neurology indicate that rivastigmine 
improved cognition, global functioning and activities of daily living in patients with 
Alzheimer's Disease. These findings were from a 6-month follow-up of 2,096 patients 
with symptomatic mild to moderately severe Alzheimer's Disease. Patients were 
randomised to receive either high dose (6-12 mg/day) or low dose (1-4mg/day) 
treatment with rivastigmine or placebo. The cognitive scale of the Alzheimer's Disease 
Assessment Scale (ADAS-cog) decreased by 4.15 points in placebo recipients, but 
improved by 0.79 points in rivastigmine recipients. The difference in scores translated 
into a clinically relevant delay in deterioration of about 6 months. According to the 
Clinician's Interview-Based Impression of Change, placebo recipients deteriorated by 
0.48 points, while high-dose rivastigmine recipients deteriorated by 0.13 points and 
low-dose recipients deteriorated by 0.16 points. The between-group differences in 
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class 
Development 
status 
Earliest 
marketing 
Clinical summary 
scores were significant. Scores on the caregiver-rated Progressive Deterioration Scale 
were significantly better in high-dose rivastigmine recipients than placebo recipients. It 
is becoming apparent that the benefits of rivastigmine are greatest in patients with 
more severe disease [14]. 
Adverse Events: Diaphoresis, Dizziness, Headache, Nausea, Vomiting 
Sabeluzole Janssen Calcium 
channel 
antagonists 
Phase II UK 
Phase III 
Belgium, 
USA 
 
 
1998/99 Sabeluzole is being evaluated for its ability to slow the progression of 
the disease rather than as a palliative treatment for the symptoms  
Therapeutic Trials:  In a double-blind placebo-controlled study, 53 patients with age-
associated memory impairment were treated with sabeluzole 20 mg/day or placebo for 
2 months. Although no significant between-group differences were detected during the 
study period, sabeluzole recipients had significant improvement over baseline in Word 
Fluency Test (WFT) scores as well as in the quality of memory function. 62% of 
sabeluzole recipients vs 49% of placebo recipients felt that their memory had improved 
[15]. 
A long-term follow-up of 34 of these patients at the end of 10 months of open 
treatment with sabeluzole found that performance in the cued recall task and WFT 
significantly improved over the long term. In contrast with the results of the short-term 
study, improvement was also seen in the selective reminding procedure. Of 23 
patients evaluated for memory function by their physician, none worsened, 5 were 
unchanged, 11 had mild improvement, 4 had moderate improvement and 3 had 
marked improvement. Over the 1-year duration of the study these patients would have 
been expected to significantly deteriorate [16]. 
Treatment with sabeluzole, 10 or 20 mg/day (bid) for 1 year, was compared with 
placebo in patients with probable Alzheimer's disease. 33 patients, ranging from 53 to 
79 years of age, underwent computerised tomographic (CT) scans. 17 patients were 
rescanned after treatment. Although sabeluzole treatment was associated with a 
reduction in the rate of deterioration, an analysis of CT scans revealed no statistically 
significant structural correlates [17]. 
In a study involving 48 patients from 1 centre participating in a multicentre study of 401 
patients, 48 weeks' treatment with sabeluzole was not associated with any significant 
difference in mean group scores for the Clinical Global Impressions scale compared 
with placebo. According to Alzheimer's Disease Assessment Scale scores, the 
placebo group deteriorated to a significantly greater degree than the sabeluzole group 
[18]. In a study involving 38 patients with partial epilepsy and memory impairment, 
sabeluzole was associated with significant improvements on the verbal long-term 
memory tests. This was thought to be potentially beneficial for epileptic patients who 
often display subjective complaints representing deficiencies in the retrieval of verbal 
30 
Drug name Manufacturer Pharmacological 
class 
Development 
status 
Earliest 
marketing 
Clinical summary 
information[19]. 
Adverse Events:  Headache, muscle/joint pain, irritability, dizziness, weight gain, 
nausea and difficulty breathing, all of mild severity, have been reported during 
treatment with sabeluzole. 
Tacrine Parke 
Davis 
Cholinesterase 
inhibitor 
Product 
licence UK. 
 
Marketed 
in USA, but 
unlikely in 
UK 
Therapeutic Trials:  Oral tacrine, in dosages of 80 to 160 mg/day, has been shown to 
improve cognitive function and behavioural deficits in a proportion of patients with 
Alzheimer's disease in 2 double-blind placebo-controlled parallel design trials of 12 
and 30 weeks' duration. A significant dose-response relationship was demonstrated at 
dosages of up to 160 mg/day. Between 40 and 58% of patients entering the studies 
were withdrawn during treatment for various reasons (mainly adverse events). 
However, of the evaluable patients in these trials, 30 to 51% achieved an improvement 
on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-C) of 
at least 4 points, compared with about 16 to 25% of those receiving placebo. The 
difference in ADAS-C scores between placebo and tacrine 80 and 160mg recipients 
remained statistically significant with intention-to-treat/last observation carried forward 
analyses. Clinician-rated global outcome measures were judged to have improved in 
25 to 42% of evaluable patients receiving tacrine 80 to 160 mg/day for 30 weeks, 
compared with 15 to 18% of placebo recipients. These results were substantiated by a 
third parallel design trial using a dose-titration phase, and by the results of some tests 
in 6 crossover design trials, although several of these studies have been criticised for 
such aspects as the possible development of training and carry-over effects, low 
dosages, low patient numbers, and administration of confounding concomitant 
medication. Nonetheless, responding patients were observed in most trials [20]. 
A trial involving 460 patients with Alzheimer's disease showed that patients without the 
Apolipoprotein E4 allele improved more with tacrine treatment than those with the 
allele [21]. 
The combination of tacrine and lecithin produced no treatment advantage over tacrine 
alone in a double-blind, crossover study involving 440 patients with Alzheimer's 
disease [22]. 
Tacrine also showed potential for the treatment of dementia in patients with 
Parkinson's disease. In the 7-patient study, the frequency of hallucinations was greatly 
reduced in all patients following tacrine treatment; they were eliminated in 5 patients. 
All patients displayed improvements according to Folstein Mini-Mental State scores 
and Unified Parkinson's Disability Rating Scale scores. Improvements in gait roughly 
corresponded to improvements in mentation [23]. 
Adverse Events: Anorexia, Ataxia, Dyspepsia, Hallucinations, Liver disorders, Rash, 
Rhinitis, Seizures, Vertigo, Diarrhoea, Elevated aminotransferase levels, Nausea, 
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Vomiting 
Xanomeline Eli Lilly Muscarinic M1 
& M4 receptor 
agonist 
Phase III 
USA 
1998/99 The pattern of adverse events, particularly gastrointestinal, associated with the oral 
formulation of xanomeline, has prompted the development of a transdermal 
xanomeline formulation,  
Therapeutic Trials:  The effects of xanomeline on cognition, behaviour and global 
status have been assessed in a double-blind, placebo-controlled trial in patients with 
mild to moderate Alzheimer's disease. 343 patients were randomised to therapy with 
xanomeline 75 mg/day, 150 mg/day or 225 mg/day, or placebo, tid for 6 months. A 
completer analysis of the cognitive subscale of the Alzheimer's Disease Assessment 
Scale disclosed a significant treatment effect with xanomeline 225 mg/day (p < 0.05 vs 
placebo). Completer analysis of the clinician's global assessment, measured by the 
Clinician's Interview-Based Impression of Change, disclosed a significant drug effect 
with xanomeline 150 and 225 mg/day (p < 0.05). Treatment emergent signs and 
symptoms analysis of the Alzheimer's Disease Symptomatology Scale indicated that 
xanomeline dose-dependently, and at the 225 mg/day dose, significantly reduced 
vocal outbursts, suspiciousness, delusions, agitation, hallucinations, wandering, 
fearfulness, compulsiveness, tearfulness, mood swings and threatening behaviour. 
Xanomeline dose-dependently prevented the onset of these symptoms in patients in 
whom they were absent at baseline. End-point analysis of the Nurses' Observational 
Scale for Geriatric Patients revealed a significant dose-dependent improvement in 
activities of daily living, social behaviour and disturbing behaviour; memory, self-care 
and mood were not significantly affected on this scale [24]. 
Adverse Events: Chest pain, Chills, Dyspepsia, Dysphagia, Faecal incontinence, 
Salivary gland disorders, Syncope, Diarrhoea, Nausea, Sweating, Vomiting 
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